S-ketamine for Adolescent Depression in Early-Onset Psychosis

S-ketamine's Potential in Adolescent Depression

A recent case report highlights the potential of intranasal S-ketamine as a treatment for adolescents with treatment-resistant depression and suicidality, particularly in those with early-onset psychosis (EOP). This report details the case of a 16-year-old male with schizophrenia who, despite achieving remission of positive symptoms with amisulpride, continued to suffer from severe depressive symptoms and chronic suicidality. The introduction of off-label intranasal S-ketamine resulted in a rapid clinical response, with a 50% reduction in the Montgomery–Åsberg Depression Rating Scale (MADRS) score within three weeks.

Mechanism and Context

S-ketamine, a derivative of ketamine, is known for its rapid-acting antidepressant effects, particularly in treatment-resistant depression (TRD) in adults. Its mechanism involves NMDA receptor antagonism, which leads to increased synaptic plasticity and neurogenesis. In this adolescent case, S-ketamine was administered intranasally, titrated to 84 mg, and resulted in not only a reduction in depressive symptoms but also an improvement in psychotic symptoms as measured by the Positive and Negative Syndrome Scale (PANSS). This dual benefit is noteworthy, especially given the historical caution against using ketamine in psychotic disorders due to potential exacerbation of symptoms.

Implications for Future Research and Policy

The positive outcomes observed in this case suggest that S-ketamine could be a viable augmentation strategy for treating depression and suicidality in adolescents with stable EOP. This could inform future clinical trials and treatment protocols, potentially leading to new guidelines for this high-risk, underserved population. The rapid response observed also underscores the need for further investigation into the long-term effects and safety of S-ketamine in younger populations.

Risks and Unknowns

Despite the promising results, the use of S-ketamine in adolescents with EOP poses several risks and unknowns. The potential for long-term side effects, the risk of dependency, and the lack of extensive research in this demographic necessitate caution. Additionally, the off-label use of S-ketamine raises ethical considerations and underscores the need for rigorous clinical trials to establish safety and efficacy standards.

Looking Forward

The case report serves as a catalyst for further exploration of S-ketamine in adolescent populations with complex psychiatric conditions. Future research should focus on larger, controlled studies to validate these findings and explore the broader applicability of S-ketamine in similar cases. As the field of psychedelic research continues to evolve, such studies could pave the way for innovative treatments that address the unique challenges faced by adolescents with EOP.